Sat.Apr 13, 2024

article thumbnail

Opinion: Readers respond to OTC antidepressants, personalized medicine, restoring trust in public health, and more

STAT

STAT publishes selected Letters to the Editor received in response to First Opinion essays to encourage robust, good-faith discussion about difficult issues. Submit a Letter to the Editor here , or find the submission form at the end of any First Opinion essay.

262
262
article thumbnail

EMCrit Wee – Ross Prager on 10 Heuristics for the New ICU Attending

EMCrit Project

10 heuristics for the new Crit Care doc from Ross Prager EMCrit Project by Scott Weingart, MD FCCM.

96
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Drug Patent Expirations for the Week of April 14, 2024

Drug Patent Watch

DEXILANT SOLUTAB (dexlansoprazole) Takeda pharms usa Patent: 8,784,885 Expiration: Apr 15, 2024 See More … For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact… Source

59
article thumbnail

Role of the Pharmacist in Institutional Readiness, Patient Readiness for Bispecifics

Pharmacy Times

Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, discusses the role of the pharmacist in relation to bispecific care team readiness and patient readiness.

53
article thumbnail

Navigating Payroll Compliance: Future-Proofing Payroll in an Evolving Regulatory Landscape

Speaker: Jennifer Hill

Payroll compliance is a cornerstone of business success, yet for small and midsize businesses, it’s becoming increasingly challenging to navigate the ever-evolving landscape of federal, state, and local regulations. Mistakes can lead to costly penalties and operational disruptions, making it essential to adopt advanced solutions that ensure accuracy and efficiency.

article thumbnail

Which pharmaceutical companies have the most cream dosed drugs?

Drug Patent Watch

This chart shows the pharmaceutical companies with the most cream dosed drugs. For a different perspective, see the most popular dosage types.

More Trending

article thumbnail

New patent for Adamas Operations drug GOCOVRI

Drug Patent Watch

Annual Drug Patent Expirations for GOCOVRI Gocovri is a drug marketed by Adamas Operations and is included in one NDA. It is available from one supplier.

52
article thumbnail

New patent for Gilead Sciences drug VOSEVI

Drug Patent Watch

Annual Drug Patent Expirations for VOSEVI Vosevi is a drug marketed by Gilead Sciences Inc and is included in one NDA. It is available from one supplier.

52
article thumbnail

New patent for Pfizer drug DAURISMO

Drug Patent Watch

Annual Drug Patent Expirations for DAURISMO Daurismo is a drug marketed by Pfizer and is included in one NDA. It is available from one supplier.

52
article thumbnail

New patent for Astellas drug XOSPATA

Drug Patent Watch

Annual Drug Patent Expirations for XOSPATA Xospata is a drug marketed by Astellas and is included in one NDA. It is available from one supplier.

52
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

New patent for Oyster Point drug TYRVAYA

Drug Patent Watch

Annual Drug Patent Expirations for TYRVAYA Tyrvaya is a drug marketed by Oyster Point Pharma and is included in one NDA. It is available from one supplier.

52
article thumbnail

New patent for Strongbridge drug RECORLEV

Drug Patent Watch

Annual Drug Patent Expirations for RECORLEV Recorlev is a drug marketed by Strongbridge and is included in one NDA. It is available from one supplier.

52